These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36723911)

  • 1. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
    Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
    JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort.
    Blazevski A; Scheltema MJ; Yuen B; Masand N; Nguyen TV; Delprado W; Shnier R; Haynes AM; Cusick T; Thompson J; Stricker P
    Eur Urol Oncol; 2020 Jun; 3(3):283-290. PubMed ID: 31103721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer.
    Zhang K; Stricker P; Löhr M; Stehling M; Suberville M; Cussenot O; Lunelli L; Ng CF; Teoh J; Laguna P; de la Rosette J
    Prostate Cancer Prostatic Dis; 2024 Sep; 27(3):525-530. PubMed ID: 38195916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Focal irreversible electroporation as primary treatment for localized prostate cancer.
    van den Bos W; Scheltema MJ; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2018 May; 121(5):716-724. PubMed ID: 28796935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Scheltema MJ; van den Bos W; Siriwardana AR; Kalsbeek AMF; Thompson JE; Ting F; Böhm M; Haynes AM; Shnier R; Delprado W; Stricker PD
    BJU Int; 2017 Nov; 120 Suppl 3():51-58. PubMed ID: 28834167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study.
    Yaxley WJ; Gianduzzo T; Kua B; Oxford R; Yaxley JW
    Investig Clin Urol; 2022 May; 63(3):285-293. PubMed ID: 35534217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer.
    Scheltema MJ; Geboers B; Blazevski A; Doan P; Katelaris A; Agrawal S; Barreto D; Shnier R; Delprado W; Thompson JE; Stricker PD
    BJU Int; 2023 Jun; 131 Suppl 4():6-13. PubMed ID: 36495481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial.
    Wang H; Xue W; Yan W; Yin L; Dong B; He B; Yu Y; Shi W; Zhou Z; Lin H; Zhou Y; Wang Y; Shi Z; Ren S; Gao X; Wang L; Xu C
    JAMA Surg; 2022 Aug; 157(8):693-700. PubMed ID: 35793110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
    de la Rosette J; Dominguez-Escrig J; Zhang K; Teoh J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke T; Ng CF; Leung CH; Sanchez-Salas R; Laguna P
    J Urol; 2023 Feb; 209(2):347-353. PubMed ID: 36441776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes.
    Collettini F; Enders J; Stephan C; Fischer T; Baur ADJ; Penzkofer T; Busch J; Hamm B; Gebauer B
    Radiology; 2019 Jul; 292(1):250-257. PubMed ID: 31161973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible Electroporation for the Ablation of Prostate Cancer.
    Karagiannis A; Varkarakis J
    Curr Urol Rep; 2019 Sep; 20(10):63. PubMed ID: 31478109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).
    Valerio M; Dickinson L; Ali A; Ramachandran N; Donaldson I; Freeman A; Ahmed HU; Emberton M
    Contemp Clin Trials; 2014 Sep; 39(1):57-65. PubMed ID: 25072507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
    Geboers B; Scheltema MJ; Blazevski A; Katelaris A; Doan P; Ali I; Agrawal S; Barreto D; Matthews J; Haynes AM; Delprado W; Shnier R; Thompson JE; Stricker PD
    BJU Int; 2023 Jun; 131 Suppl 4():14-22. PubMed ID: 36594205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    Blazevski A; Scheltema MJ; Amin A; Thompson JE; Lawrentschuk N; Stricker PD
    BJU Int; 2020 Mar; 125(3):369-378. PubMed ID: 31725935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.
    Valerio M; Dickinson L; Ali A; Ramachadran N; Donaldson I; Mccartan N; Freeman A; Ahmed HU; Emberton M
    J Urol; 2017 Mar; 197(3 Pt 1):647-654. PubMed ID: 27697580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
    Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
    Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.
    Blazevski A; Gondoputro W; Scheltema MJ; Amin A; Geboers B; Barreto D; Haynes AM; Shnier R; Delprado W; Agrawal S; Thompson JE; Stricker PD
    BMC Urol; 2022 Mar; 22(1):28. PubMed ID: 35236338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.